From: Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years
Variable
Denosumab (n = 120)
ZA(n = 122)
P - value
Total incidence of SSEs
10/120
21/122
0.04*a
SSE incidence
within 2 years
3/120
4/122
0.21a
after 2 years
7/120
17/122